A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)

Organon and Co666 enrolled

Overview

The primary objective of this trial was to identify at least one next generation ring (NGR) that demonstrates inhibition of ovulation (which was considered confirmed if in the subset of participants ovulation was observed in less than 15% of the participants at any time during the 3 treatment cycles of the study) and cycle control that was non-inferior to NuvaRing®, as judged by the incidence of breakthrough bleeding and/or spotting (BTB-S) during Cycle 3. The primary hypothesis was that at least 1 of the 6 NGRs would show inhibition of ovulation and cycle control during Treatment Cycle 3 that is non-inferior to NuvaRing®, as judged by the incidence of BTB-S.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

666

Conditions

Contraception

Interventions

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 35 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Body mass index (BMI) ≥18 and ≤35 * Regular cycles from 24 to 35 days in length, with an intra-individual variation of ±3 days permitted within this range * Good physical and mental health Exclusion Criteria: * Diabetes mellitus with vascular involvement * Presence of a severe or multiple risk factor(s) for venous or arterial thrombosis * Severe dyslipoproteinemia * Severe hypertension * Presence or history of pancreatitis associated with severe hypertriglyceridaemia * Presence or history of severe hepatic disease * Undiagnosed vaginal bleeding * Known or suspected pregnancy * Participation in another investigational drug study within 30 days prior to screening visit * History of malignancy ≤5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer * Documented abnormal cervical smear result in 6 months prior to screening visit * Sterilization using a fallopian tube occlusion device (e.g., Essure method) * Sex hormone therapy within 2 months prior to screening visit for purpose other than contraception, or injectable hormonal contraception within 6 months prior to screening

Outcomes

Primary Outcomes

Percentage of Participants With Ovulation Incidence, by Cycle

Ovulation was defined as having 2 or more consecutive progesterone concentrations \>16 nmol/L within 5 days, confirmed by ultrasound evidence of ovulation (follicular rupture or preceding presence of a follicle-like structure \>15 mm in size).

Time frame: Day 1 of Treatment Cycle 1 through Day 28 of Treatment Cycle 3 (Up to ~92 days)

Percentage of Participants With Progesterone Concentrations >16 Nmol/L, by Cycle

Maximum progesterone (Max P) was defined as the maximum progesterone value. Ovulation was defined as 2 or more consecutive progesterone concentrations \>16 nmol/L within 5 days during the 3 treatment cycles, supported by ultrasound evidence of ovulation. The Max P values greater than 16 nmol/L are presented by vaginal ring group and cycle.

Time frame: Day 1 of Treatment Cycle 1 through Day 28 of Treatment Cycle 3 (Up to ~92 days)

Percentage of Participants With Breakthrough Bleeding and/or Spotting During Cycle 3

Breakthrough bleeding and/or spotting (BTB-S) is defined as any bleeding or spotting episode that occurred during the expected non-bleeding period that was neither an early nor a continued withdrawal bleeding. Bleeding = any bloody vaginal discharge that required one or more sanitary pads or tampons per day; Spotting = any bloody vaginal discharge that required no sanitary pads or tampons per day.

Time frame: Day 1 Cycle 3 through Day 28 Cycle 3 (Up to ~28 days)

Secondary Outcomes

Percentage of Participants With Absence of Withdrawal Bleeding and/or Spotting During Cycle 2

Withdrawal bleeding and/or spotting is considered any bleeding or spotting episode that starts during or continues into the expected bleeding period (i.e., when the ring has been removed the last week of the cycle). Absence of withdrawal bleeding is no withdrawal bleeding and/or spotting episodes during an expected bleeding period when the ring has been removed.

Time frame: Day 1 Cycle 2 through Day 28 Cycle 2 (Up to ~28 days)

Intensity of Withdrawal Bleeding During Cycle 2

Intensity of withdrawal bleeding during Cycle 2 was defined as the ratio of the number of withdrawal bleeding days divided by the number of withdrawal bleeding and/or spotting days. Withdrawal bleeding and/or spotting is considered any bleeding or spotting episode that starts during or continues into the expected bleeding period (i.e., when the ring has been removed the last week of the cycle). Absence of withdrawal bleeding is no withdrawal bleeding and/or spotting episodes during an expected bleeding period when the ring has been removed.

Time frame: Day 1 Cycle 2 through Day 28 Cycle 2 (Up to ~28 days)

Intensity of Breakthrough Bleeding and/or Spotting During Cycle 3

Intensity of breakthrough bleeding and/or spotting (BTB-S) during Cycle 3 was defined as the ratio of the number of breakthrough bleeding days divided by the number of breakthrough bleeding and/or spotting days. Breakthrough bleeding and/or spotting (BTB-S) is defined as any bleeding or spotting episode that occurred during the expected non-bleeding period that was neither an early nor a continued withdrawal bleeding. Bleeding = any bloody vaginal discharge that required one or more sanitary pads or tampons per day; Spotting = any bloody vaginal discharge that required no sanitary pads or tampons per day.

Time frame: Day 1 Cycle 3 through Day 28 Cycle 3 (Up to ~ 28 days)

Percentage of Participants Who Experienced At Least One Adverse Event

Time frame: Up to ~92 days

Percentage of Participants Who Experienced At Least One Serious Adverse Event

A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is a cancer, is associated with an overdose; or is another important medical event deemed such by medical or scientific judgment.

Time frame: Up to ~92 days

Percentage of Participants Who Experienced At Least One Drug-Related Adverse Event

An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug. A drug-related AE was defined as any AE for which there is reasonable possibility of drug relationship as assessed by the Investigator.

Time frame: Up to ~92 days

Percentage of Participants With Any Drug-Related Serious Adverse Event

Time frame: Up to ~92 days

Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event

Time frame: Up to ~92 days